Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H27F3N6OS.C4H4O4 |
| Molecular Weight | 572.6 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CC(C)(C)C1=NC(=CC(=N1)N2CCN(CCCSC3=NC=CC(=O)N3)CC2)C(F)(F)F
InChI
InChIKey=KQMGYGQUUXCWBL-WLHGVMLRSA-N
InChI=1S/C20H27F3N6OS.C4H4O4/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18;5-3(6)1-2-4(7)8/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30);1-2H,(H,5,6)(H,7,8)/b;2-1+
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | C20H27F3N6OS |
| Molecular Weight | 456.528 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Abbott Laboratories was developing the selective dopamine D3 receptor antagonist, ABT-925 (formerly A 437203), for the treatment of schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT 925 was undergoing phase II clinical development for the treatment of schizophrenia. However, development was discontinued in December 2007.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia. | 2011 Apr |
|
| Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. | 2013 Feb |
|
| Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. | 2015 Sep |
Sample Use Guides
Schizophrenia: One hundred fifty-five patients were assessed over a 6-week double-blind treatment period (placebo: n = 48; ABT-925 50 mg once daily [QD]: n = 53; ABT-925 150 mg QD: n = 54). No statistically significant treatment effect was observed with ABT-925 50 mg QD or 150 mg QD compared with placebo on primary or secondary efficacy end points. Pharmacokinetic parameter estimates increased with dose in a linear fashion. ABT-925 50 mg QD and 150 mg QD were generally well tolerated, with adverse event profiles similar to that of placebo.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:13:52 GMT 2023
by
admin
on
Sat Dec 16 02:13:52 GMT 2023
|
| Record UNII |
DMH23OL273
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9916103
Created by
admin on Sat Dec 16 02:13:52 GMT 2023 , Edited by admin on Sat Dec 16 02:13:52 GMT 2023
|
PRIMARY | |||
|
220519-07-3
Created by
admin on Sat Dec 16 02:13:52 GMT 2023 , Edited by admin on Sat Dec 16 02:13:52 GMT 2023
|
PRIMARY | |||
|
DMH23OL273
Created by
admin on Sat Dec 16 02:13:52 GMT 2023 , Edited by admin on Sat Dec 16 02:13:52 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
